Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer(,,)

OBJECTIVE: Farletuzumab is a humanized monoclonal antibody that binds to folate receptor alpha, over-expressed in epithelial ovarian cancer (EOC) but largely absent in normal tissue. Previously, carboplatin plus pegylated liposomal doxorubicin showed superior progression-free survival and an improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Kenneth H., Jelovac, Danijela, Armstrong, Deborah K., Schwartz, Benjamin, Weil, Susan C., Schweizer, Charles, Alvarez, Ronald D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729193/
https://www.ncbi.nlm.nih.gov/pubmed/26644263
http://dx.doi.org/10.1016/j.ygyno.2015.11.031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729193/
https://www.ncbi.nlm.nih.gov/pubmed/26644263
http://dx.doi.org/10.1016/j.ygyno.2015.11.031

Ejemplares similares